Statins and reporting signals for amnesia: a pharmacovigilance analysis based on adverse event reporting database
Frontiers in Pharmacology · 11.08.2026 · 17
DOI: 10.3389/fphar.2026.1858243 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 11.08.2026. Verfasst von Le Wang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Shanxi Provincial Mental Health Center, Taiyuan Psychiatric Hospital, Taiyuan, China. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
This study aimed to explore the disproportionality reporting signals of amnesia associated with different statins based on a spontaneous adverse event database, so as to provide preliminary pharmacovigilance evidence for subsequent clinical safety evaluation and further pharmacoepidemiological verification. Materials and methods This study employed pharmacovigilance analysis methods to monitor and analyze adverse event signals associated with seven commonly used statins. Additionally, subgroups were stratified by gender (male, female) and age (18, 45, and 65 years) to investigate the potential associations between statins and amnesia across different populations. Furthermore, a Weibull distribution analysis was used to assess the onset time of adverse events.
Results
A total of 56,401 statin-related adverse event reports were included, among which 1,108 valid cases were coded as amnesia. Significant positive pharmacovigilance signals were identified for atorvastatin (n = 326, ROR = 2.82, 95% CI: 2.53–3.15, P < 0.001), simvastatin (n = 600, ROR = 4.94, 95% CI: 4.55–5.35, P < 0.001), pravastatin (n = 68, ROR = 4.77, 95% CI: 3.76–6.06, P < 0.001), and lovastatin (n = 26, ROR = 6.96, 95% CI: 4.73–10.24, P < 0.001). Subgroup analyses stratified by gender and age further identified heterogeneous pharmacovigilance signals across distinct populations. Moreover, Weibull distribution analysis also revealed unique distribution patterns among different statin agents.
Conclusion
This study identified significant positive pharmacovigilance signals between certain statins and amnesia. The findings of this study provide preliminary disproportionality signals regarding statin-related amnesia, offering exploratory pharmacovigilance references for subsequent safety evaluation and further pharmacoepidemiological validation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Shanxi Provincial Mental Health Center, Taiyuan Psychiatric Hospital, Taiyuan, China.
- Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, China.
Zitieren
APA
Wang, L., Yang, N., & Ren, Z. (2026). Statins and reporting signals for amnesia: a pharmacovigilance analysis based on adverse event reporting database. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1858243
Vancouver
Wang L, Yang N, Ren Z. Statins and reporting signals for amnesia: a pharmacovigilance analysis based on adverse event reporting database. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1858243
BibTeX
@article{Wang2026,
author = {Wang, Le and Yang, Nan and Ren, Zhiyong},
title = {Statins and reporting signals for amnesia: a pharmacovigilance analysis based on adverse event reporting database},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1858243}
}
EUVIMED